Cipla's mfg facility in Goa gets two observations from US FDA
This story was originally published at 17:29 IST on 17 April 2026
Register to read our real-time news.Informist, Friday, Apr. 17, 2026
--US FDA issues two observations to Cipla's Goa facility
MUMBAI – Cipla Ltd. Friday said the US Food and Drug Administration conducted an inspection at the company's manufacturing facility at Verna in Goa and issued two observations in Form 483. The company will work closely with the US FDA to address these issues comprehensively within stipulated time, Cipla said.
The US FDA Form 483 is issued to a company when investigators observe conditions that may constitute violations of the US Food Drug and Cosmetic Act and related Acts. The US regulator started this investigation at the Goa facility on Apr. 6. under good manufacturing practices and pre-approval inspection.
For the quarter ended December, Cipla had reported consolidated net profit of INR 6.76 billion on revenue of INR 70.74 billion. On Friday, shares of the company ended nearly 1% higher at INR 1,240.80 on the National Stock Exchange. End
Reported by Eshitva Prakash
Edited by Akul Nishant Akhoury
For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.
Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd. by NSE Data & Analytics Ltd., a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt. Ltd.
Informist Media Tel +91 (22) 6985-4000
Send comments to feedback@informistmedia.com
© Informist Media Pvt. Ltd. 2026. All rights reserved.
To read more please subscribe
Share this Story:
